The changing face of pharma in the precision era

Natasha Cowan|6th September 2019

Nancy Brandt is not your typical medical information specialist. While medical affairs teams are usually focused on developing scientific communications about a product or service for healthcare professionals, she has been tasked with preparing a top 20 biopharma company for the future of precision medicine.

For pharma, it’s clear the future lies in making the right partnerships. Precision medicine equates understanding the patient’s molecular makeup and using this information and other clinical data to find targeted treatments. However, right now the policies and regulations are still being written. New stakeholders are entering the fray and bringing with them novel technologies that can improve patient outcomes.

We are on the brink of a new way of practising medicine and pharmaceutical companies have the opportunity to shape this future, but this hinges on collaborating with the right people and listening to what the complex network of stakeholders are asking of them.

This means moving away from a product-specific way of thinking to develop a deep insight into how society is changing as precision medicines emerge. As a result, Nancy is immersed in understanding the patient journey and developing agile ways of working to ensure the organisation stays one step ahead of novel developments. Armed with this information, she can then develop partnerships that will fuel innovative communications for the 21st-century patient and the complex stakeholder network, from doctors to policymakers.

Here, she reveals how she is embracing this new way of working and the lessons she has learned along the way.

Top 5 tips for a multi-indication product launch

Sana Rahim|8th July 2020

Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.

read more

If our patients are diverse, why are clinical trials so white?

Ling Song|22nd June 2020

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.

read more

How to run an engaging virtual workshop

Blue Latitude Health|15th June 2020

Our strategic consultants give their top tips for running an engaging virtual workshop. 

read more